secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001104659-24-083722
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck Q2 2024: revenue $16.1B (+7% YoY); raises sales outlook but lowers EPS guidance on EyeBio charge
--------------------------------------------------------------------------------

- Q2 revenue $16.1B (+7% YoY, +11% ex-FX); GAAP EPS $2.14, Non-GAAP EPS $2.28; KEYTRUDA sales $7.3B (+16%).
- Full-year 2024 sales outlook raised to $63.4-64.4B (from $63.1-64.3B); Non-GAAP EPS guidance lowered to $7.94-8.04 (from $8.53-8.65) due to $1.3B EyeBio acquisition charge.
- WINREVAIR generated $70M in Q2 sales; over 1,000 patients treated since U.S. launch in March 2024.
- Completed acquisitions of EyeBio and Elanco's Aqua Business in July 2024; $0.51/share EPS impact from EyeBio.
- CDC's ACIP unanimously recommended CAPVAXIVE; positive EU CHMP opinion for WINREVAIR in PAH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465924083722/0001104659-24-083722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465924083722/tm2420272d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-083722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer